Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11296)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 7, 2019 (publication date) through Apr 10, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548 [PMID: 31210708 DOI: 10.3748/wjg.v25.i21.2539] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i21/2539.htm |
| Number | Citing Articles |
| 1 |
Shanshan Wang, Miaomiao Bai, Qingyan Shu, Zhengan Liu, Yirui Shao, Kang Xu, Xia Xiong, Hongnan Liu, Yao Li. Modulating Effect of Paeonol on Piglets With Ulcerative Colitis. Frontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.846684
|
| 2 |
Gizette Sperinde, Diana Montgomery, Daniel T. Mytych. Clinical Immunogenicity Risk Assessment for a Fusion Protein. The AAPS Journal 2020; 22(3) doi: 10.1208/s12248-020-00447-y
|
| 3 |
Panu Wetwittayakhlang, Gynter Kotrri, Talat Bessissow, Peter L. Lakatos. How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?. Expert Opinion on Biological Therapy 2024; 24(6): 433 doi: 10.1080/14712598.2024.2371049
|
| 4 |
Antonello Di Paolo, Giacomo Luci. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Frontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.610806
|
| 5 |
Debbie S. Deben, Dennis R. Wong, Adriaan A. van Bodegraven. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease. Expert Opinion on Drug Metabolism & Toxicology 2021; 17(12): 1433 doi: 10.1080/17425255.2021.2029406
|
| 6 |
Oliwia Zakerska-Banaszak, Liliana Łykowska-Szuber, Michał Walczak, Joanna Żuraszek, Aleksandra Zielińska, Marzena Skrzypczak-Zielińska. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022; 10(4): 151 doi: 10.3390/toxics10040151
|
| 7 |
Bianca JC van den Bosch, Marieke JH Coenen. Pharmacogenetics of Inflammatory Bowel Disease. Pharmacogenomics 2021; 22(1): 55 doi: 10.2217/pgs-2020-0095
|
| 8 |
Biao Yu, Min Wang, Bo Teng, Suresh Veeraperumal, Peter Chi-Keung Cheung, Saiyi Zhong, Kit-Leong Cheong. Partially Acid-Hydrolyzed Porphyran Improved Dextran Sulfate Sodium-Induced Acute Colitis by Modulation of Gut Microbiota and Enhancing the Mucosal Barrier. Journal of Agricultural and Food Chemistry 2023; 71(19): 7299 doi: 10.1021/acs.jafc.2c08564
|
| 9 |
Philip E. Empey, Jason H. Karnes, Julie A. Johnson. Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the Field.
Annual Review of Pharmacology and Toxicology
2025; 65(1): 111 doi: 10.1146/annurev-pharmtox-061724-080718
|
| 10 |
Shixian Hu, Werna T. Uniken Venema, Harm-Jan Westra, Arnau Vich Vila, Ruggero Barbieri, Michiel D. Voskuil, Tjasso Blokzijl, Bernadien H. Jansen, Yanni Li, Mark J. Daly, Ramnik J. Xavier, Gerard Dijkstra, Eleonora A. Festen, Rinse K. Weersma. Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-21458-z
|
| 11 |
Imam Hossen, Wu Hua, Arshad Mehmood, Rifat Nowshin Raka, Song Jingyi, Jin Jian-Ming, Xu Min, Ashbala Shakoor, Cao Yanping, Chengtao Wang, Xiao Junsong.
Glochidion ellipticum Wight extracts ameliorate dextran sulfate sodium-induced colitis in mice by modulating nuclear factor kappa-light-chain-enhancer of activated B cells signalling pathway. Journal of Pharmacy and Pharmacology 2021; 73(3): 410 doi: 10.1093/jpp/rgaa044
|
| 12 |
Marileen M. C. Prins, Francesca P. Giugliano, Manon van Roest, Stan F. J. van de Graaf, Pim J. Koelink, Manon E. Wildenberg. Thiopurines correct the effects of autophagy impairment on intestinal healing – a potential role for ARHGAP18/RhoA. Disease Models & Mechanisms 2021; 14(4) doi: 10.1242/dmm.047233
|
| 13 |
Aze Wilson, Qian Wang, Yun-Hee Choi, Terry Ponich, James C. Gregor, Nilesh Chande, Brian Yan, Michael Sey, Melanie Beaton, Richard B. Kim. Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. Clinical and Translational Gastroenterology 2021; 12(4): e00332 doi: 10.14309/ctg.0000000000000332
|
| 14 |
Debbie S. Deben, Rob H. Creemers, Arjan J. van Adrichem, Roosmarie Drent, Audrey H. H. Merry, Mathie P. G. Leers, Adriaan A. van Bodegraven, Dennis R. Wong. A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-20197-5
|
| 15 |
Xinyun Qin, Zhineng Liu, Keyi Nong, Xin Fang, Wanyan Chen, Bin Zhang, Yijia Wu, Zihan Wang, Huiyu Shi, Xuemei Wang, Haiwen Zhang. Porcine-derived antimicrobial peptide PR39 alleviates DSS-induced colitis via the NF-κB/MAPK pathway. International Immunopharmacology 2024; 127: 111385 doi: 10.1016/j.intimp.2023.111385
|
| 16 |
Eva Haasis, Anna Bettenburg, Axel Lorentz. Effect of Intermittent Fasting on Immune Parameters and Intestinal Inflammation. Nutrients 2024; 16(22): 3956 doi: 10.3390/nu16223956
|
| 17 |
Justyna Lorenc-Góra, Dariusz Waniczek, Zenon P. Czuba, Mariusz Kryj, Zbigniew Lorenc, Małgorzata Muc-Wierzgoń. Assessment of the Utility of Selected Inflammatory Markers in Correlation with Magnetic Resonance Enterography (MRE) Findings in the Diagnosis of Crohn’s Disease. Biomolecules 2025; 15(1): 116 doi: 10.3390/biom15010116
|
| 18 |
Zohra Chadli, Ibtissem Hannachi, Manel Ben Belgacem, Arwa Guediche, Haifa Ben Romdhane, Emna Kerkeni, Lamia Hamdi, Ahlem Slama, Amel Chaabane, Nadia Ben Fredj, Naceur A Boughattas, Leila Safer, Karim Aouam. Effects of genetic and clinical factors on thiopurine drugs pharmacokinetics in Tunisian patients. Pharmacogenomics 2024; 25(10-11): 441 doi: 10.1080/14622416.2024.2406739
|
| 19 |
Ji Young Chang, Jae Hee Cheon. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precision and Future Medicine 2021; 5(4): 151 doi: 10.23838/pfm.2021.00128
|
| 20 |
Matthew B. Stanton, Mark A. Solinski, Stephen B. Hanauer. Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine. Expert Review of Clinical Immunology 2025; 21(4): 461 doi: 10.1080/1744666X.2025.2461584
|
| 21 |
Matthias Kelm, Christoph-Thomas Germer, Nicolas Schlegel, Sven Flemming. The Revival of Surgery in Crohn’s Disease—Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis. Biomedicines 2021; 9(10): 1317 doi: 10.3390/biomedicines9101317
|
| 22 |
Narges Norouzkhani, Mahbobeh Faramarzi, Sara Ghodousi Moghadam, Mohammad Amin Karimi, Javad Shokri Shirvani, Ali Bahari, Mahdie ShojaeiBaghini, Saeid Eslami, Hamed Tabesh. Identification of the informational and supportive needs of patients diagnosed with inflammatory bowel disease: a scoping review. Frontiers in Psychology 2023; 14 doi: 10.3389/fpsyg.2023.1055449
|
| 23 |
Naomi Karmi, Amber Bangma, Lieke M. Spekhorst, Hendrik M. van Dullemen, Marijn C. Visschedijk, Gerard Dijkstra, Rinse K. Weersma, Michiel D. Voskuil, Eleonora A. M. Festen, Cinzia Ciccacci. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease. PLOS ONE 2021; 16(9): e0256860 doi: 10.1371/journal.pone.0256860
|
| 24 |
Mengfan Luo, Qiaoyue Yuan, Mingzhen Liu, Xingye Song, Yingjie Xu, Tao Zhang, Xiaoqun Zeng, Zhen Wu, Daodong Pan, Yuxing Guo. Astaxanthin nanoparticles ameliorate dextran sulfate sodium-induced colitis by alleviating oxidative stress, regulating intestinal flora, and protecting the intestinal barrier. Food & Function 2023; 14(21): 9567 doi: 10.1039/D3FO03331G
|
| 25 |
Matthias Kelm, Friedrich Anger, Robin Eichlinger, Markus Brand, Mia Kim, Joachim Reibetanz, Katica Krajinovic, Christoph-Thomas Germer, Nicolas Schlegel, Sven Flemming. Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn’s Disease. Journal of Clinical Medicine 2021; 10(4): 731 doi: 10.3390/jcm10040731
|
| 26 |
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem. A review article of inflammatory bowel disease treatment and pharmacogenomics. Beni-Suef University Journal of Basic and Applied Sciences 2023; 12(1) doi: 10.1186/s43088-023-00361-0
|
| 27 |
Björn Carlsson, Louise Karlsson, Andreas Ärlemalm, Sophie Sund, Malin Lindqvist Appell. Quantification of deoxythioguanosine in human DNA with LC-MS/MS, a marker for thiopurine therapy optimisation. Analytical and Bioanalytical Chemistry 2024; 416(29): 6711 doi: 10.1007/s00216-024-05581-6
|
| 28 |
M.A. Danilov, A.A. Demidova, A.V. Leontev, V.V. Tsvirkun. Early Ileocecal Resection for Crohn’s Disease. Dokazatel'naya gastroenterologiya 2023; 12(3): 10 doi: 10.17116/dokgastro20231203110
|
| 29 |
Pearl Avery. The cost of treating inflammatory bowel disease: step-up vs step-down, therapeutic drug monitoring and personalised medicine. Gastrointestinal Nursing 2021; 19(4): 18 doi: 10.12968/gasn.2021.19.4.18
|
| 30 |
Hossein Shahdadi Sardou, Paria Rahnama Vosough, Mohammadreza Abbaspour, Abbas Akhgari, Thozhukat Sathyapalan, Amirhossein Sahebkar. A review on curcumin colon-targeted oral drug delivery systems for the treatment of inflammatory bowel disease. Inflammopharmacology 2023; 31(3): 1095 doi: 10.1007/s10787-023-01140-0
|
| 31 |
Anastasia Konidari, David Dickens, Munir Pirmohamed. Inflammatory Bowel Disease: A Personalized Approach. Frontiers in Pediatrics 2021; 8 doi: 10.3389/fped.2020.620545
|
| 32 |
Mijin Lee, Sukyung Kim, Jeong Yee, Hye Sun Gwak, Kyung Hee Choi. Analysis of Pharmacogenetic Information in Korea Drug Labels. Korean Journal of Clinical Pharmacy 2021; 31(1): 21 doi: 10.24304/kjcp.2021.31.1.21
|
| 33 |
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem. Association of genetic polymorphism of NUDT15, TPMT and ITPA gene in the toxicity and efficacy of azathioprine-based regimen in Egyptian inflammatory bowel disease patients. Beni-Suef University Journal of Basic and Applied Sciences 2023; 12(1) doi: 10.1186/s43088-023-00340-5
|
| 34 |
Xudong Tang, Yangyang Shang, Hong Yang, Yalan Song, Shan Li, Yusi Qin, Jingyi Song, Kang Chen, Yang Liu, Dinglin Zhang, Lei Chen. Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-46025-0
|
| 35 |
Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.897936
|